Los Angeles Times -- When Tysabri first came on the market in 2004 to treat multiple sclerosis, patients hailed it as a wonder drug. Clinical trials showed that it was twice as effective as other medications at preventing recurrences of MS. It also appeared to slow the overall course of the disease.
